Newsroom

COLUMBUS, Ohio--(BUSINESS WIRE)--Worthington Steel Announces Launch of $900 Million Senior Secured Notes Offering...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones International Internet UCITS ETF 25.05.2026 FDNI.LN IE00BT9PVG14 450,002.00 USD 8,221,001.18 18.269  ...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION   (a) Full name of discloser: Massachusetts Financial Services Company (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficia...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION   (a) Full name of discloser: Massachusetts Financial Services Company (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficia...

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management plans to provide a business update after the close of regular stock market hours on Tuesday, May 26, 2026. Veradigm management plans to host an investor conference call and webcast to discuss the Company’s update on Wednesday, May 27th, at 8:00 a.m. Eastern Time. Update Call Details Veradigm plans to issue a press release afte...

RAYNHAM, Mass.--(BUSINESS WIRE)--DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced a definitive agreement to acquire selective rights to develop, manufacture and commercialize Gemtrack technology across its Joints portfolio, including shoulder, hip and knee, for both navigation and robotic applications. Gemtrack is a proprietary tracking technology developed by MinMaxMedical (MMM), a Grenoble-based pioneer in medtech and surgical innovation. Pending succe...

CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, biopharmaceutical company with a recently approved novel, monthly, small-dose, third-generation PCSK9 inhibitor, LEROCHOL® (lerodalcibep-liga), today announced results from two oral and two poster presentations at the European Atherosclerosis Society meeting, held in Athens, Greece, May 24-26, 2026. Oral Presentations, May 25, 2026: The Long-Term Efficacy and Safety of Lerodalcibep in Homozygous Familial Hypercholestero...

TAMPA, Fla.--(BUSINESS WIRE)--Exzeo Group Inc. (NYSE: XZO) today announced that its Board of Directors has authorized a new program and adopted a corresponding plan under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, to purchase up to $12 million of the company’s common shares, subject to market conditions. The authorization and plan are effective immediately. “This share repurchase program reflects our confidence in the long-term value of Exzeo Group. The company continues to...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the new 8890B GC and 8860B GC with GC Assist. GC Assist is the new, advanced instrument intelligence that provides system monitoring, built-in troubleshooting, and remote connectivity to analytical instrumentation within the laboratory’s secure network. These systems enable higher performance and productivity across gas chromatography analyses. The new systems are designed to help laboratorie...

BEIJING--(BUSINESS WIRE)--Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® plat...